8-K
IMAC Holdings, Inc. (BACK)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or Section 15(d) of the Securities Exchange Act of 1934
Dateof Report (Date of earliest event reported): September 4, 2025
IMACHoldings, Inc.
(Exactname of registrant as specified in its charter)
| Delaware | 001-38797 | 83-0784691 |
|---|---|---|
| (State or other jurisdiction of<br><br> <br>incorporation or organization) | (Commission<br><br> <br>File Number) | (I.R.S. Employer<br><br> <br>Identification Number) |
| 3401 Mallory Lane, Suite 100<br><br> <br>Franklin, Tennessee | 37067 | |
| --- | --- | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’stelephone number, including area code: (844) 266-4622
(Formername or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, par value $0.001 per share | BACK | OTC Markets Group, Inc. |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item1.01 Entry into a Material Definitive Agreement.
The information provided in Item 2.03 of this Current Report on Form 8-K is incorporated by reference into this Item 1.01.
On September 4, 2025, Ignite Proteomics, LLC, a wholly owned subsidiary of IMAC Holdings, Inc. (the “Company”), entered into a Statement of Work (“SOW”) with Inova Health Care Services (“Inova”) under their existing Master Services Agreement (“MSA”). Under the SOW, Ignite will analyze up to 600 tumor samples using its Reverse Phase Protein Array (“RPPA”) technology to generate biomarker data across a panel of cancer-relevant proteins. Results will be provided to Inova’s Molecular Tumor Board to support assessment of therapy response and resistance in gastrointestinal cancers. The maximum contract value is $420,000 with $175,000 payable upon execution and the remainder billed based on delivered reports. A copy of the Agreement is filed as Exhibit 10.1 to this Current Report.
Item7.01 Regulation FD Disclosure
On September 10, 2025, the Company issued a press release announcing the collaboration, a copy of which is furnished as Exhibit 99.1 to this Current Report.
Item9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description |
|---|---|
| 10.1 | Statement of Work with Inova Health Care Services signed September 4, 2025 (certain portions redacted). |
| 99.1 | Press Release dated September 10, 2025. |
| 104 | Cover<br> Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: September 10, 2025
| IMAC HOLDINGS, INC. | |
|---|---|
| By: | /s/ Faith Zaslavsky |
| Name: | Faith<br> Zaslavsky |
| Title: | Chief<br> Executive Officer |
Exhibit 10.1
Exhibit99.1
Ignite Proteomics Announces Collaboration with Inova Health on a Biomarker Study for Late-Stage Cancers
TheFirst Precision Oncology Trial to Use a Functional Proteomics and Phosphoproteomics Assay for Treatment Decision Making in a Pan-TumorStudy
Golden,CO – September 10, 2025
Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (OTCQB: BACK), today announced that it has entered into a research collaboration with Inova Health to apply Ignite’s Reverse Phase Protein Array (RPPA) technology to tumor samples from patients, primarily with late-stage gastrointestinal cancers. The data provided from the analysis by RPPA will be used to help oncologists select from multiple treatment options where no current guidance is available.
Under the agreement, Ignite will analyze up to 600 tumor samples to generate actionable biomarker data across a panel of cancer-relevant drug target proteins, including HER2, RET, MHC-II, EGFR, TROP2, AKT, ERK, and others. Results will be provided to Inova’s Molecular Tumor Board to assess therapy response and resistance in gastrointestinal cancers based on specific protein or phosphor-protein levels.
“This collaboration with Inova underscores the expanding applications of our RPPA technology in solid tumors,” said Faith Zaslavsky, President and CEO of Ignite Proteomics. “By partnering with Inova’s Molecular Tumor Board, we aim to accelerate precision medicine approaches for patients with gastrointestinal cancers.”
“At Inova, our mission is to bring the most advanced science into the clinic for patients who have run out of standard options” said Timothy Cannon, MD, Director of the Molecular Tumor Board and Co-Director of the Gastrointestinal Cancer Program at Inova. “This collaboration gives our Molecular Tumor Board a new lens—a direct measure of the activity of the protein drug targets themselves that you cannot get from genomics analysis. This key missing information could better help guide treatment decisions in late-stage cancers, where every additional month of effective therapy matters.”
While specific financial terms were not disclosed, the agreement represents one of the most significant research services collaborations to date for Ignite Proteomics and is expected to contribute meaningfully to the Company’s 2025 revenue.
AboutIgnite Proteomics
Ignite Proteomics, a subsidiary of IMAC Holdings, delivers pathway-level protein analytics to guide precision oncology. Operating a CLIA-certified, CAP-accredited laboratory, Ignite’s clinical RPPA assay quantifies 32 phospho- and total-protein biomarkers from minute biopsy material, with many more in research stages, enabling oncologists and drug developers to match patients with the most effective targeted and immune therapies.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the expected scope, timeline, and potential outcomes of the collaboration with Inova. Forward-looking statements are based on current assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Important factors that could affect actual results include, among others, the successful completion of the research project, and the validity and reproducibility of study data. Except as required by law, IMAC Holdings undertakes no obligation to update forward-looking statements contained herein to reflect events or circumstances after the date of this release.
Investor & Media Contact
investors@imacholdings.com
| www.igniteproteomics.com